#United States #New York #Pomerantz LLP #ADC Therapeutics #ADCT

Investigation of ADC Therapeutics by Pomerantz Law Firm

The Pomerantz Law Firm has initiated an investigation concerning the company ADC Therapeutics SA, listed under the ticker symbol ADCT on NYSE. This inquiry is aimed at safeguarding the interests of investors who have been affected by potentially misleading information regarding the company's operations and securities. The investigation primarily revolves around claims of securities fraud and improperly conducted business practices by ADC and certain individuals in its leadership.

Pomerantz LLP is a well-regarded firm known for its work in corporate and securities law, often acting on behalf of aggrieved investors. Founded more than eight decades ago, it has a reputation for fighting back against corporate wrongdoing and securing significant damages for class members in such instances.

Background on ADC Therapeutics and Recent Developments

Recently, on June 3, 2026, ADC Therapeutics released top-line data from its Phase 3 LOTIS-5 trial, which evaluated the safety and efficacy of its treatment, ZYNLONTA® (loncastuximab tesirine-lpyl), in conjunction with rituximab for patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). While the findings indicated a modest increase in progression-free survival duration by 1.4 months, they also revealed alarming stats concerning patient safety. Notably, the trial recorded 27 deaths among the patients treated with Zynlonta in contrast to just nine among those receiving traditional immunotherapy.

Following the announcement, ADC’s stock experienced a dramatic fall—dropping by $2.05, or a staggering 66.56%, impacting the share price to close at $1.03 per share by June 5, 2026. This volatility has raised significant concerns among investors who may feel misled regarding the therapeutic benefits and risks of the new treatment. As such, the investigation by Pomerantz is crucial to determine if proper disclosures were made to investors regarding the trials and results.

The Role of Pomerantz Law Firm

Pomerantz LLP has a long-standing history of addressing issues related to securities fraud and protecting the rights of shareholders. They invite any investors affected by the situation with ADC Therapeutics to reach out for assistance. Investors are encouraged to contact Danielle Peyton at the firm to share their experiences and explore potential claims as the investigation unfolds.

The firm's commitment to their clients' rights and welfare echoes in their ongoing efforts to gather substantial awards for class members who have suffered losses due to corporate misconduct. For more information on how to join this investigation and the class action proceedings, interested parties are urged to connect directly with Pomerantz.

In light of these recent developments, it is clear that the situation surrounding ADC Therapeutics not only impacts its operational standing in the biotechnology sector but also highlights the importance of transparent communication between companies and their investors, particularly in clinical trial disclosures.

Understanding the gravity of this situation, Pomerantz LLP remains dedicated to uncovering the veracity of the claims made by ADC, ensuring that all investors are informed and can take necessary actions to protect their interests as more details come to light.